788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi

Abstract

This post-hoc, pooled analysis of 4 trials aimed to identify factors associated with achieving target HbA1c <7.0% in people with type 2 diabetes (T2D) treated with iGlarLixi. People with T2D advancing from oral (LixiLan-O), GLP-1 RA (LixiLan-G), or insulin (LixiLan-L; SoliMix) therapies were randomized to iGlarLixi vs active comparators for 26 or 30 weeks. HbA1c was assessed at baseline (BL) and end of treatment, and responses were classified by the achievement or non-achievement of target HbA1c <7.0% (<53 mmol/mol). Predictive factors for achieving target were analyzed by univariable and multivariable stepwise logistic regression. Pooled analyses (N=1455) showed mean [SD] HbA1c, T2D duration, and insulin total daily dose at BL were lower in those who achieved (8.0 [0.7]%, 10.7 [6.7] y, 0.23 [0.15] U/kg) vs those who did not achieve (8.4 [0.7]%, 12.1 [7.0] y, 0.29 [0.15] U/kg) target HbA1c, respectively. Predictors of achieving target glycemic response (p<0.05) included lower BL HbA1c, lower T2D duration, and lower insulin dose at BL, as well as weight change (decrease) from BL. Age, BMI, and fasting plasma glucose at BL had no predictive value (Table). In conclusion, HbA1c, T2D duration, and insulin dose at BL, in addition to weight change from BL, were predictors of achieving target HbA1c <7.0% in people with T2D treated with iGlarLixi. Disclosure A.Y.Cheng: Advisory Panel; Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc., Other Relationship; Diabetes Canada, Research Support; Applied Therapeutics Inc., Speaker's Bureau; Abbott, AstraZeneca, Bayer Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., HLS Therapeutics Inc., Medtronic, Novo Nordisk, Sanofi, Insulet Corporation, Dexcom, Inc., Bausch Health, Canada. J.P.Frias: Advisory Panel; Becton, Dickinson and Company, Pfizer Inc., Sanofi, Consultant; Akero Therapeutics, Inc., 89bio, Inc., Aimmune, Boehringer Ingelheim Inc., Eli Lilly and Company, Carmot Therapeutics, Inc., Echosens, Merck & Co., Inc., Metacrine, Inc., Novo Nordisk, Pfizer Inc., Sanofi, Employee; Ionis Pharmaceuticals, Research Support; Akero Therapeutics, Inc., 89bio, Inc., Altimmune, Axcella Health Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Intercept Pharmaceuticals, Inc., Carmot Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Metacrine, Inc., Novo Nordisk, Oramed Pharmaceuticals, Novartis, Pfizer Inc., Sanofi, Speaker's Bureau; Eli Lilly and Company, Sanofi. C.Guja: Advisory Panel; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Speaker's Bureau; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Servier Laboratories, Viatris Inc. F.Lauand: Employee; Sanofi. L.Melas-melt: None. A.Alvarez: Employee; Sanofi. E.Souhami: Employee; Sanofi, Stock/Shareholder; Sanofi. J.Rosenstock: Advisory Panel; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Novo Nordisk, Oramed Pharmaceuticals, Sanofi, Zealand Pharma A/S, Intarcia Therapeutics, Inc., Hanmi Pharm. Co., Ltd., Research Support; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis, Novo Nordisk, Pfizer Inc., Sanofi, Intarcia Therapeutics, Inc. Funding Sanofi